EP News: Clinical

Kar et  al (Circulation April 6, 2021;Epub ahead of print, PMID XXXX) evaluated the WATCHMAN FLX left atrial appendage (LAA) closure device in patients in whom oral anticoagulation is indicated but are candidates for a nonpharmaceutical alternative in a prospective multicenter study. The primary safety en d point was the occurrence of one of the following events: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure at 12-month follow-up.
Source: Heart Rhythm - Category: Cardiology Authors: Tags: EP News Source Type: research